Pfizer to buy Biohaven for $11.8 billion, reveals the Financial Times

Tuesday, 10 May 2022, 2:22 pm

The venerable Financial Times this morning revealed that US pharma giant Pfizer is in the advanced stages of buying Biohaven, a US-listed firm that has been working on treatments for migraines. Below is the link:

A few minutes later the Pfizer and Biohaven announced the transaction, with the former offering $148.50 a share (or just over $11 billion) in cash for the latter. Below is a link to the press release:..


Register for free to see rest of this article and all public articles from Betaville

Login / Register

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Login to join the conversation